Sermorelin research monograph — the GHRH(1-29) analog and its clinical history

Sermorelin is one of the longest-standing growth-hormone-axis peptides, with a
clinical history that distinguishes it from the newer secretagogues.

Chemical identity & structure.
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of
human growth-hormone-releasing hormone (GHRH) — the GHRH(1-29) fragment, which
is the shortest fragment that retains GHRH's full biological activity. It is the
unmodified parent of the GRF(1-29)-derived analogs such as CJC-1295.

Mechanism of action.
Sermorelin is a GHRH-receptor agonist. It acts on the pituitary to stimulate the
synthesis and pulsatile release of growth hormone, preserving the body's own
regulatory feedback. Because it works upstream of the pituitary rather than
supplying growth hormone directly, its effect is self-limiting in a way that
exogenous hGH is not. Its half-life is short — minutes — which shaped how it was
used clinically.

Key research findings.
Sermorelin's clinical research focused on growth hormone deficiency, including
use as a diagnostic agent to assess pituitary GH-release capacity, and on
GH-deficiency treatment in children.

The research / citation base.
Sermorelin has a notable regulatory history: it was previously FDA-approved
(brand name Geref) and used clinically, then its commercial production was
discontinued — a business decision, not a safety withdrawal. It therefore has a
real historical clinical evidence base, though it is no longer a marketed
approved product in the US. It is sometimes available through compounding
pharmacies.

Research protocols in the literature.
Clinical use was by subcutaneous administration; its short half-life meant
dosing was timed to support natural nocturnal GH pulses. Research-grade material
is a lyophilized powder for reconstitution.

Quality & sourcing notes.
A batch-specific COA should confirm the GHRH(1-29) sequence by mass spectrometry
and report HPLC purity. Confirm the COA describes sermorelin specifically and
not a different GRF analog (the modified GRF(1-29) and CJC variants are
different molecules).

*Research-use note: Educational summary of published research. Sermorelin is not
currently a marketed approved product in the US; this is research context only
and not medical advice.*